Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare Biotechnology

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc

Bullboard Posts

Comment by TheRock07on Jul 18, 2016 10:39am

200 Views

Post# 25061418

RE:RE:RE:Investment in Pediapharm...

Its a small but tidy investment.
Within 3-4 years, it will be generating $20-$25 million in sales.

Thats will be attractive bundle for GUD by then.

Adding more PDP shares now makes lots of sense.

No cash was included.
Indeed, no cash was needed by PDP, as it is cash rich.

So, in a sense, an unusual move whose full motivation can only be speculated about..

Bullboard Posts

Anaergia expands relationship with PepsiCo